Callidatas US was launching Nefecon, a capsule treatment for IgA Nephropathy (IgAN) for the US in November 2021. Nefecon is an orphan drug for rare diseases. They also needed to be preparing for Fruquintinib in 2023. They had no IT strategy nor any Systems in place to enable and support the launch. The commercialization would focus on Nephrologists and hospitals, about 3000 high-value targets. As a rare disease drug, it was critical to locate and identify patients. Distribution would be through an exclusive specialty pharmacy.
Implemented a Multi-Years IT strategy and Roadmap, provided support for Program Management and Solution/Vendor Evaluation and Selection. Design overall Enterprise IT Architecture and IT Governance and Security. Define IT Budget and set up IT Organization. IT was ready to support the launch on time and on budget. CEO Renee Lucander provided the following quote “Patrick Retif has done an outstanding job designing and building the IT landscape needed to support and enable our first commercial product launch in the US”